Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0QDCHN
ADC Name
PRO-1160
Synonyms
PRO 1160; PRO1160
   Click to Show/Hide
Organization
ProfoundBio (Suzhou) Co., Ltd.
Drug Status
Phase 1/2
Indication
In total 3 Indication(s)
Nasopharyngeal carcinoma [ICD11:2B6B]
Phase 2
Non Hodgkin lymphoma [ICD11:2B33]
Phase 2
Renal cell carcinoma [ICD11:2C90]
Phase 2
Drug-to-Antibody Ratio
8
Structure
Antibody Name
Undisclosed
Antigen Name
CD70 antigen (CD70)
  Antigen Info 
Payload Name
Exatecan
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Linker Name
Cys-11 ADC linker
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
LD038
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05721222
Phase 1/2
Phase 1/2 study of PRO1160 in patients with renal cell carcinoma (RCC), nasopharyngeal carcinoma (NPC), or non-Hodgkin lymphoma (NHL).
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05721222  Clinical Status Phase 1/2
Clinical Description Phase 1/2 study of PRO1160 in patients with renal cell carcinoma (RCC), nasopharyngeal carcinoma (NPC), or non-Hodgkin lymphoma (NHL).
References
Ref 1 Phase 1/2 Study of PRO1160 in Patients With Renal Cell Carcinoma (RCC), Nasopharyngeal Carcinoma (NPC), or Non-Hodgkin Lymphoma (NHL), NCT05721222

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.